Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives $123.22 Consensus Target Price from Analysts

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has received an average recommendation of "Hold" from the twenty ratings firms that are currently covering the stock, MarketBeat reports. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $123.22.

A number of research firms have recently issued reports on ZBH. Wolfe Research initiated coverage on shares of Zimmer Biomet in a research note on Tuesday, September 10th. They issued a "peer perform" rating on the stock. Robert W. Baird decreased their price target on Zimmer Biomet from $155.00 to $145.00 and set an "outperform" rating on the stock in a research note on Thursday, August 8th. Wells Fargo & Company lifted their price objective on Zimmer Biomet from $110.00 to $117.00 and gave the company an "equal weight" rating in a research note on Thursday, October 31st. UBS Group cut their price objective on Zimmer Biomet from $112.00 to $107.00 and set a "sell" rating on the stock in a report on Thursday, August 8th. Finally, Evercore ISI lowered their target price on Zimmer Biomet from $113.00 to $110.00 and set an "in-line" rating for the company in a report on Tuesday, October 1st.

Institutional Trading of Zimmer Biomet

Institutional investors have recently bought and sold shares of the business. Empowered Funds LLC lifted its stake in Zimmer Biomet by 50.6% during the first quarter. Empowered Funds LLC now owns 3,757 shares of the medical equipment provider's stock worth $496,000 after purchasing an additional 1,262 shares during the last quarter. Bleakley Financial Group LLC lifted its position in shares of Zimmer Biomet by 6.2% during the 1st quarter. Bleakley Financial Group LLC now owns 2,271 shares of the medical equipment provider's stock worth $300,000 after buying an additional 132 shares during the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Zimmer Biomet by 22.4% in the 1st quarter. Kingsview Wealth Management LLC now owns 3,225 shares of the medical equipment provider's stock valued at $426,000 after buying an additional 590 shares in the last quarter. Blair William & Co. IL grew its position in shares of Zimmer Biomet by 3.7% in the 1st quarter. Blair William & Co. IL now owns 33,364 shares of the medical equipment provider's stock valued at $4,403,000 after buying an additional 1,184 shares during the last quarter. Finally, Tocqueville Asset Management L.P. raised its stake in Zimmer Biomet by 1.4% during the 1st quarter. Tocqueville Asset Management L.P. now owns 14,007 shares of the medical equipment provider's stock worth $1,849,000 after acquiring an additional 196 shares in the last quarter. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Up 3.4 %

Shares of Zimmer Biomet stock traded up $3.69 during mid-day trading on Friday, hitting $112.54. The stock had a trading volume of 2,599,995 shares, compared to its average volume of 1,534,878. The firm has a 50-day moving average of $106.28 and a two-hundred day moving average of $110.11. The firm has a market cap of $22.40 billion, a P/E ratio of 21.40, a price-to-earnings-growth ratio of 2.00 and a beta of 1.02. The company has a quick ratio of 0.70, a current ratio of 1.36 and a debt-to-equity ratio of 0.38. Zimmer Biomet has a 12-month low of $101.47 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.74. Zimmer Biomet had a return on equity of 12.95% and a net margin of 14.27%. The company had revenue of $1.82 billion during the quarter, compared to analysts' expectations of $1.80 billion. During the same quarter last year, the firm earned $1.65 earnings per share. The firm's quarterly revenue was up 4.1% compared to the same quarter last year. Sell-side analysts forecast that Zimmer Biomet will post 7.99 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Thursday, October 31st. Investors of record on Monday, September 30th were issued a $0.24 dividend. This represents a $0.96 annualized dividend and a yield of 0.85%. The ex-dividend date was Monday, September 30th. Zimmer Biomet's dividend payout ratio (DPR) is presently 18.25%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.